A company dedicated to enhancing cancer screening, detection, and care has confirmed the appointment of Dr Adam Hill as its new CEO, effective from October 1.
Dr Adam Hill succeeds Geoffrey Hamilton-Fairley, the founder, who will now serve as the vice-chairman of the board of directors. Dr Hill, who initially joined the firm as Chief Medical Officer and Chief Scientific Officer earlier this year, brought extensive experience from his previous role at McLaren Applied Technologies. There, he was the Chief Strategy Officer and managed a portfolio of health programmes developed with major pharmaceutical and medical device companies.
With a career spanning industry, academia, and healthcare delivery, Dr Hill has been influential in developing technology and commercial strategies within the medical device and diagnostics industry. His senior leadership roles in both private and publicly listed companies are complemented by advisory and government policy positions. Since joining the firm, Dr Hill has led the research and development team and a strategic review, aiming to harness the potential of the company’s proprietary auto-antibody-based platform for cancer-related antigen profiling.
This strategic review reaffirmed the platform’s capability for early detection, improved care, and innovative personalised approaches to cancer treatment.
Founder Geoffrey Hamilton-Fairley, who became part of the company in 2005 when it was established as a university spin-out, spearheaded the transition to a commercial entity. His leadership saw the launch of two early detection blood tests for lung and liver cancer in the US and the expansion into China, Europe, and the Middle East through significant collaborative partnerships.
Meinhard Schmidt, the non-executive chairman, praised Hamilton-Fairley’s vision and dedication, which have positioned the firm as a leader in cancer immunodiagnostics. Schmidt highlighted the experienced international team, robust internal science, and the development platform capable of fostering new collaborations and attracting research partnerships as key achievements under Hamilton-Fairley’s tenure.
With the expansion of the company’s programme and product portfolio, the focus is now on leveraging new technology to maximise value and broaden the scope beyond lung and liver cancer diagnostics.
Welcoming Dr Hill as the new CEO, Schmidt acknowledged his expertise in personalised diagnostics and healthcare optimisation. Hamilton-Fairley expressed confidence in Hill’s leadership, stating, ‘The company is well-positioned for an exciting future, and it is now time to transition to new leadership who will take our products and technology through clinical development and broad global commercialisation.’
Dr Hill emphasised the evolving landscape of oncology and the potential for significantly improved cancer survivorship. He looks forward to collaborating with the board and the company’s highly skilled executive and scientific teams to advance immunodiagnostic solutions through clinical development to benefit patients worldwide. ‘As the field of oncology sits on the cusp of dramatically improved cancer survivorship, I look forward to working with the company’s experienced board, and its highly talented executive and scientific teams to take our immunodiagnostic solutions through clinical development and into the hands of clinicians to improve patient outcomes,’ he stated.
The appointment of Dr Adam Hill as the new CEO marks a significant milestone for the company, promising continued innovation and enhanced cancer care through advanced diagnostics.
